We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
-10.41%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$447M
AUM Growth
+$467K
Cap. Flow
+$81.7M
Cap. Flow %
18.28%
Top 10 Hldgs %
73.55%
Holding
30
New
4
Increased
1
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
SKYE icon
Skye Bioscience
SKYE
+$121M
2
ERAS icon
Erasca
ERAS
+$11.7M
3
TECX
Tectonic Therapeutic
TECX
+$10.4M
4
BHVN icon
Biohaven
BHVN
+$5.93M
5
EYPT icon
EyePoint Inc
EYPT
+$698K

Top Sells

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$25.8M
2
MRUS
Merus
MRUS
+$24.7M
3
RNAM
Avidity Biosciences
RNAM
+$17M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$218K
5
CDTX
Cidara Therapeutics
CDTX
+$14

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SKYE icon
1
Skye Bioscience
SKYE
$20.5M
$81.5M 18.24%
+10,179,505
New +$121M
TRDA icon
2
Entrada Therapeutics
TRDA
$282M
$62.8M 14.05%
4,408,379
– –
ELVN icon
3
Enliven Therapeutics
ELVN
$4.15B
$61M 13.65%
2,610,875
-1,225,100
-32% -$25.8M
DNTH icon
4
Dianthus Therapeutics
DNTH
$5.8B
$31.9M 7.14%
1,232,965
-9,064
-0.7% -$218K
CLDX icon
5
Celldex Therapeutics
CLDX
$2.96B
$18.4M 4.12%
497,270
– –
BHVN icon
6
Biohaven
BHVN
$2.01B
$16.3M 3.65%
469,972
+150,000
+47% +$5.93M
TYRA icon
7
Tyra Biosciences
TYRA
$1.91B
$15M 3.36%
939,298
– –
PHVS icon
8
Pharvaris
PHVS
$2.25B
$15M 3.35%
797,600
– –
PRAX icon
9
Praxis Precision Medicines
PRAX
$8.52B
$14.1M 3.15%
340,000
– –
ERAS icon
10
Erasca
ERAS
$6.19B
$12.8M 2.85%
+5,405,404
New +$11.7M
VKTX icon
11
Viking Therapeutics
VKTX
$3.8B
$12.6M 2.82%
237,560
– –
MLTX icon
12
MoonLake Immunotherapeutics
MLTX
$1.48B
$12.4M 2.78%
282,313
– –
CNTA
13
DELISTED
Centessa Pharmaceuticals
CNTA
$11.2M 2.51%
1,245,000
– –
TECX
14
Tectonic Therapeutic
TECX
$527M
$10.6M 2.38%
+646,524
New +$10.4M
VRDN icon
15
Viridian Therapeutics
VRDN
$2.13B
$9.58M 2.14%
736,595
– –
SLN
16
Silence Therapeutics
SLN
$504M
$9.05M 2.02%
476,200
– –
ANAB icon
17
AnaptysBio
ANAB
$1.59B
$8.96M 2.01%
357,733
– –
GHRS icon
18
GH Research
GHRS
$1.93B
$6.68M 1.49%
572,665
– –
COGT icon
19
Cogent Biosciences
COGT
$6.64B
$6.66M 1.49%
790,440
– –
VOR icon
20
Vor Biopharma
VOR
$1.16B
$6.36M 1.42%
318,086
– –
SCPH
21
DELISTED
scPharmaceuticals
SCPH
$5.22M 1.17%
1,200,647
– –
RLYB icon
22
Rallybio
RLYB
$84.6M
$4.87M 1.09%
453,841
– –
QTTB icon
23
Q32 Bio
QTTB
$450M
$4.52M 1.01%
251,994
– –
ADVM
24
DELISTED
Adverum Biotechnologies
ADVM
$3.72M 0.83%
541,666
– –
MRSN
25
DELISTED
Mersana Therapeutics
MRSN
$2.62M 0.59%
52,200
– –
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q2 2024 Portfolio in Review

As of Q2 2024, 5AM Venture Management held 30 positions worth $447M, up 0.1% from $447M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

5AM Venture Management deployed $81.7M of net new capital in Q2 2024, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Skye Bioscience: 10,179,505 shares worth $81.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Enliven Therapeutics, an estimated $25.8M trimmed.

  • 5AM Venture Management's largest Q2 2024 buy was Skye Bioscience: 10,179,505 shares worth $81.5M.
  • 5AM Venture Management added most to Biohaven in Q2 2024, an estimated $5.93M increase.
  • 5AM Venture Management's biggest Q2 2024 reduction was Enliven Therapeutics, cutting an estimated $25.8M.
  • 5AM Venture Management fully exited Merus in Q2 2024, selling an estimated $24.7M.
  • 5AM Venture Management's ten largest holdings make up 74% of its $447M portfolio in Q2 2024.
  • 5AM Venture Management opened 4 new positions and closed 2 in Q2 2024.
  • 5AM Venture Management's portfolio value rose 0.1% quarter-over-quarter to $447M.

Based on 5AM Venture Management's 13F filing for Q2 2024, filed 14 Aug 2024.